Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Gordon Scott has been an active investor and ...